COMMUNIQUÉS West-GlobeNewswire

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease

02/04/2024 - 00:08

Established Low Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial DSMB Determination to Proceed with Medium Dose Cohort Dosing MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or [...]

Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023

01/04/2024 - 23:43

MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and [...]

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01/04/2024 - 23:30

NEW YORK and SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule [...]

R1 RCM to Release First Quarter 2024 Results on May 8, 2024

01/04/2024 - 23:00

MURRAY, Utah, April 01, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, [...]

Lifeward CEO Issues Open Letter to Shareholders on Progress to Finalize Exoskeleton Medicare Payment Rate

01/04/2024 - 22:30

Collaboration with CMS on final payment rate focuses on commercial transaction values for the latest generation of ReWalk Exoskeleton CMS indicates that recently issued fee schedule which omitted exoskeletons can be [...]

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01/04/2024 - 22:20

RESEARCH TRIANGLE PARK, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 3,000 [...]

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

01/04/2024 - 22:15

Positive results from confirmatory Phase 3 RESILIENT study reported in December 2023 position Tonmya™ for fibromyalgia for NDA submission second half of 2024; pre-NDA meeting with FDA scheduled for second quarter 2024 [...]

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

01/04/2024 - 22:15

Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024 CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- ProMIS [...]

Integra LifeSciences Completes the Acquisition of Acclarent, Inc.

01/04/2024 - 22:15

PRINCETON, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has successfully completed its acquisition of [...]

NeurAxis to Host Fourth Quarter and Full Year 2023 Results and Business Update Call on Tuesday, April 9, 2024

01/04/2024 - 22:15

CARMEL, Ind., April 01, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and [...]

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01/04/2024 - 22:10

REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of covalent [...]

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

01/04/2024 - 22:10

MIRAMAR, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel [...]

Gritstone bio Announces Proposed Public Offering

01/04/2024 - 22:10

EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that it has [...]

Rapafusyn Announces Multiple Presentations at the 2024 Drug Discovery Chemistry Conference

01/04/2024 - 22:08

BALTIMORE, April 01, 2024 (GLOBE NEWSWIRE) -- Rapafusyn Pharmaceuticals is pleased to announce two upcoming presentations at Cambridge Health Institute’s 12 th Annual Oral Peptides & Macrocyclics Conference, April 1 [...]

Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year of 2023

01/04/2024 - 22:05

The Company Reports Another Record in Annual Revenue PLAINVIEW, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO) today announced its operating results for the three months and year ended [...]

Stryker to announce financial results for its first quarter of fiscal year 2024

01/04/2024 - 22:05

Portage, Michigan, April 01, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for first quarter of fiscal year 2024 on Tuesday, April 30, 2024. A press release will be issued [...]

Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024

01/04/2024 - 22:05

TARRYTOWN, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its first quarter 2024 financial and operating results on Thursday, May 2, 2024, [...]

SIGA Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX®

01/04/2024 - 22:05

NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on health security and infectious disease, announced today that it entered into an [...]

Acutus Medical Reports Fourth Quarter and Full Year 2023 Financial Results

01/04/2024 - 22:05

CARLSBAD, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB) today reported results for the fourth quarter and full year ended December 31,2023. Recent Highlights [...]